Loading…
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.4B | $96M | $49M | $81M | 23.9% | 17.9% | -156.4% |
| 2024 | $1.2B | $-43M | $-87M | $42M | -61.2% | 17.4% | -465.2% |
| 2023 | $1.0B | $59M | $24M | $56M | 84.7% | 15.1% | -32.5% |
| 2022 | $909M | $68M | $35M | $32M | 82.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 908.91 | 1,046.19 | 1,228.41 | 1,448.68 |
| Operating Revenue | - | 908.91 | 1,046.19 | 1,228.41 | 1,448.68 |
| Cost Of Revenue | - | 723.04 | 837.88 | 984.04 | 1,155.97 |
| Gross Profit | - | 185.87 | 208.31 | 244.37 | 292.72 |
| Operating Expense | - | 133.88 | 167.36 | 307.29 | 220.02 |
| Selling General And Administration | - | 133.88 | 167.36 | 307.29 | 220.02 |
| Total Expenses | - | 856.92 | 1,005.25 | 1,291.33 | 1,375.98 |
| Operating Income | - | 51.99 | 40.95 | -62.92 | 72.70 |
| Total Operating Income As Reported | - | 51.99 | 40.95 | -62.92 | 72.70 |
| EBITDA | - | 68.15 | 58.81 | -43.43 | 96.42 |
| Normalized EBITDA | - | 68.15 | 58.81 | -43.43 | 96.42 |
| EBIT | - | 51.59 | 40.58 | -63.20 | 74.09 |
| Interest Expense | - | 1.93 | 2.86 | 3.28 | 0.66 |
| Net Interest Income | - | -1.93 | -2.86 | -3.28 | -0.66 |
| Other Non Operating Income Expenses | - | -0.40 | -0.37 | -0.28 | 1.39 |
| Other Income Expense | - | -0.40 | -0.37 | -0.28 | 1.39 |
| Interest Expense Non Operating | - | 1.93 | 2.86 | 3.28 | 0.66 |
| Net Non Operating Interest Income Expense | - | -1.93 | -2.86 | -3.28 | -0.66 |
| Pretax Income | - | 49.66 | 37.72 | -66.48 | 73.42 |
| Tax Provision | - | - | 0 | 4.56 | 24.46 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 49.66 | 37.72 | -71.03 | 48.96 |
| Net Income From Continuing And Discontinued Operation | - | 35.42 | 23.90 | -87.29 | 49.22 |
| Net Income From Continuing Operation Net Minority Interest | - | 35.42 | 23.90 | -87.29 | 49.22 |
| Net Income | - | 35.42 | 23.90 | -87.29 | 49.22 |
| Net Income Common Stockholders | - | 35.42 | 0 | -110.05 | 49.22 |
| Net Income Including Noncontrolling Interests | - | 49.66 | 37.72 | -71.03 | 48.96 |
| Normalized Income | - | 35.42 | 23.90 | -87.29 | 49.22 |
| Diluted NI Availto Com Stockholders | - | 35.42 | 0 | -110.05 | 49.22 |
| Basic Average Shares | - | 60.84 | 60.84 | 62.01 | 62.39 |
| Diluted Average Shares | - | 60.84 | 60.84 | 62.01 | 63.30 |
| Reconciled Depreciation | - | 16.56 | 18.23 | 19.77 | 22.34 |
| Reconciled Cost Of Revenue | - | 723.04 | 837.88 | 984.04 | 1,155.97 |
| Minority Interests | - | -14.24 | -13.82 | -16.25 | 0.26 |
| General And Administrative Expense | 13.03 | - | - | - | - |
| Salaries And Wages | 13.03 | - | - | - | - |
| Other Operating Expenses | - | -3.38 | - | - | - |
| Selling And Marketing Expense | 118.09 | 137.26 | - | - | - |
| Otherunder Preferred Stock Dividend | - | - | 23.90 | 22.76 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services, Inc.this co. | GRDN | $2.6B | 52.49 | 12.56 | 23.9% | 26.50 |
| Soleno Therapeutics, Inc. | SLNO | $2.8B | 132.26 | 6.14 | 4.6% | 96.72 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.7B | -170.10 | 14.49 | -8.5% | 1582.53 |
| Disc Medicine, Inc. | IRON | $2.7B | -12.80 | 3.67 | -28.7% | -12.77 |
| Definium Therapeutics, Inc. | DFTX |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $2.7B |
| -14.59 |
| 8.07 |
| -55.3% |
| -13.82 |
| Alumis Inc. | ALMS | $2.6B | -10.68 | 8.63 | -80.8% | -5.66 |
| Tarsus Pharmaceuticals, Inc. | TARS | $2.6B | -39.09 | 7.56 | -19.3% | -45.85 |
| IDEAYA Biosciences, Inc. | IDYA | $2.6B | -22.58 | 2.51 | -11.1% | -16.04 |
| Heartflow, Inc. | HTFL | $2.5B | -21.27 | 8.26 | -38.8% | -26.44 |
| Peer Median | - | -17.93 | 7.81 | -24.0% | -13.30 | |